Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
nab-paclitaxel + carboplatin is a combination chemotherapy regimen primarily for advanced non-small-cell lung cancer (NSCLC) and other solid tumors. Nab-paclitaxel, marketed as Abraxane, is a formulation of paclitaxel bound to albumin nanoparticles, enhancing drug delivery and reducing hypersensitivity reactions. Carboplatin is a platinum-based agent causing DNA crosslinking and apoptosis. The combination disrupts microtubule function (nab-paclitaxel) and induces DNA damage (carboplatin), leading to cancer cell death. Administered intravenously in 21-day cycles, it's effective as first-line therapy for advanced NSCLC patients with good performance status.
- Brand names
- Abraxane
- Other names
- paclitaxel protein-bound particles + carboplatinalbumin-bound paclitaxel + carboplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on nab-paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + carboplatin.